Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40265-020-01424-7 http://scihub22266oqcxt.onion/10.1007/s40265-020-01424-7 33151482!7643089!33151482     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drugs 2020 ; 80 (18): 1961-1972 Nephropedia Template TP {{tp|p=33151482|t=2020. Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity |pdf=|usr=}}{{33151482}} gab.com Text Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity JO: Drugs http://www.kidney.de/pget.php?&tw=1&pmid=33151482 #FOAvip BACKGROUND: Treatment decisions for Coronavirus Disease 2019 (COVID-19) depend on disease severity, but the prescribing pattern by severity and drivers of therapeutic choices remain unclear. OBJECTIVES: The objectives of the study were to evaluate pharmacological treatment patterns by COVID-19 severity and identify the determinants of prescribing for COVID-19. METHODS: Using electronic health record data from a large Massachusetts-based healthcare system, we identified all patients aged >/= 18 years hospitalized with laboratory-confirmed COVID-19 from 1 March to 24 May, 2020. We defined five levels of COVID-19 severity at hospital admission: (1) hospitalized but not requiring supplemental oxygen; (2-4) hospitalized and requiring oxygen </= 2, 3-4, and >/= 5 L per minute, respectively; and (5) intubated or admitted to an intensive care unit. We assessed the medications used to treat COVID-19 or as supportive care during hospitalization. RESULTS: Among 2821 patients hospitalized for COVID-19, we found inpatient mortality increased by severity from 5% for level 1 to 23% for level 5. As compared to patients with severity level 1, those with severity level 5 were 3.53 times (95% confidence interval 2.73-4.57) more likely to receive a medication used to treat COVID-19. Other predictors of treatment were fever, low oxygen saturation, presence of co-morbidities, and elevated inflammatory biomarkers. The use of most COVID-19 relevant medications has dropped substantially while the use of remdesivir and therapeutic anticoagulants has increased over the study period. CONCLUSIONS: Careful consideration of disease severity and other determinants of COVID-19 drug use is necessary for appropriate conduct and interpretation of non-randomized studies evaluating outcomes of COVID-19 treatments. Twit Text FOAVip Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity ????Drugs http://www.kidney.de/pget.php?&tw=1&pmid=33151482 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33151482 #FOAvip English Wikipedia <ref>{{Cite pmid|33151482}}</ref> Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity #MMPMID33151482 Lin KJ; Schneeweiss S; Tesfaye H; D'Andrea E; Liu J; Lii J; Murphy SN; Gagne JJ Drugs 2020[Dec]; 80 (18): 1961-1972 PMID33151482show ga BACKGROUND: Treatment decisions for Coronavirus Disease 2019 (COVID-19) depend on disease severity, but the prescribing pattern by severity and drivers of therapeutic choices remain unclear. OBJECTIVES: The objectives of the study were to evaluate pharmacological treatment patterns by COVID-19 severity and identify the determinants of prescribing for COVID-19. METHODS: Using electronic health record data from a large Massachusetts-based healthcare system, we identified all patients aged >/= 18 years hospitalized with laboratory-confirmed COVID-19 from 1 March to 24 May, 2020. We defined five levels of COVID-19 severity at hospital admission: (1) hospitalized but not requiring supplemental oxygen; (2-4) hospitalized and requiring oxygen /= 5 L per minute, respectively; and (5) intubated or admitted to an intensive care unit. We assessed the medications used to treat COVID-19 or as supportive care during hospitalization. RESULTS: Among 2821 patients hospitalized for COVID-19, we found inpatient mortality increased by severity from 5% for level 1 to 23% for level 5. As compared to patients with severity level 1, those with severity level 5 were 3.53 times (95% confidence interval 2.73-4.57) more likely to receive a medication used to treat COVID-19. Other predictors of treatment were fever, low oxygen saturation, presence of co-morbidities, and elevated inflammatory biomarkers. The use of most COVID-19 relevant medications has dropped substantially while the use of remdesivir and therapeutic anticoagulants has increased over the study period. CONCLUSIONS: Careful consideration of disease severity and other determinants of COVID-19 drug use is necessary for appropriate conduct and interpretation of non-randomized studies evaluating outcomes of COVID-19 treatments. |*COVID-19 Drug Treatment[MESH] |*Hospitalization[MESH] |Adolescent[MESH] |Adrenal Cortex Hormones/therapeutic use[MESH] |Adult[MESH] |Age Factors[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Anticoagulants/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |Biological Products/therapeutic use[MESH] |Body Mass Index[MESH] |COVID-19/epidemiology/*mortality[MESH] |Comorbidity[MESH] |Comoros[MESH] |Drug Therapy, Combination[MESH] |Drug Utilization[MESH] |Extracorporeal Membrane Oxygenation/statistics & numerical data[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Oxygen Inhalation Therapy/methods[MESH] |Pandemics[MESH] |Racial Groups[MESH] |Respiration, Artificial/statistics & numerical data[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Sex Factors[MESH] |Smoking/epidemiology[MESH]Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Pat(epmc).pdf DeepDyve Pubget Overpricing